Diabetes Screening for Patients with Schizophrenia or Bipolar Disorder

This report is a public document prepared on behalf of the Centers for Medicare & Medicaid Services Qualified Entity program. It presents findings related to diabetes screening rates among individuals with schizophrenia or bipolar disorder who are prescribed antipsychotic medications. The report utilizes data from the Healthcare Effectiveness Data and Information Set (HEDIS®) standard measure, focusing on the year 2017. It highlights the significant health risks associated with type 2 diabetes mellitus (T2DM) in this population, emphasizing the importance of routine screening to improve health outcomes. The findings indicate that approximately 72% of patients were screened for diabetes, but rates varied significantly based on health insurance categories. The report details the methodology for measuring screening rates, including the criteria for inclusion and exclusion of patients, and provides a breakdown of screening rates by insurance type. The analysis underscores the need for continuous performance measurement to monitor variations in screening practices across different demographics and regions.